Bedrijfsoverzicht
FibroBiologics, Inc. is a clinical-stage biotechnology enterprise focused on the development and commercialization of fibroblast-based therapies designed to treat patients suffering from chronic diseases. The company operates within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures prior to potential product approval. As of the latest data, the company holds a market capitalization of $6.13M and employs 15 individuals to execute its strategic initiatives. The combination of a market cap of $6.13M and reported annual revenue that is not currently available suggests the entity is in an early-stage growth phase where value is derived from intellectual property and pipeline progress rather than established sales streams. This valuation scale indicates that the market prices the company primarily on its future potential for therapeutic breakthroughs in wound care and chronic disease management, rather than current profitability or cash generation capabilities.
Financiële gezondheid
The company reports revenue of N/A for the trailing twelve months, while net income stands at $-18,646,000 and EBITDA is recorded at $-16,405,000. The substantial gap between the reported revenue (which is currently non-existent or negligible) and the significant net loss reveals a cost structure dominated by research and development expenses rather than cost of goods sold, typical for pre-commercial biotechnology firms. Free cash flow is reported at $-9,968,125, which indicates that the company is consuming its available liquidity to fund operations and clinical trials, thereby limiting immediate financial flexibility without further external capital raising. All three margin metrics—the gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting a business model where revenue has not yet materialized to cover operating costs or generate profit. On the liability side, the company holds $4.89M in cash against $2.41M in debt, resulting in a debt-to-equity ratio of 39.15. Despite the elevated debt-to-equity figure, the balance sheet appears conservative regarding immediate solvency because the cash reserves exceed total debt obligations. The current ratio is 3.61, indicating a strong liquidity position where current assets are more than three times current liabilities, providing ample buffer for short-term obligations. Return on Equity is -419.4% and Return on Assets is -79.8%, metrics that reveal management is currently destroying equity and utilizing assets to fund operations rather than generating returns, a common characteristic in the pre-revenue stages of biotechnology development.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to the absence of positive earnings, while the forward P/E is reported at -0.25. The difference between these metrics, specifically the negative forward P/E, implies that analysts or market models project continued losses in the near term before the company can achieve profitability. The price-to-book ratio is 0.73, which indicates that the market is valuing the company at less than its net asset value, suggesting a discount relative to the book value of its assets. Alternative valuation metrics such as the price-to-sales ratio (N/A) and EV/EBITDA (-0.13) are utilized in this context; the negative EV/EBITDA reflects the company's lack of earnings power and suggests valuation is driven by asset backing or pipeline value rather than earnings multiples. The stock has exhibited significant volatility, trading between a 52-week high of $30.60 and a 52-week low of $1.03. Based on the available price range, the current valuation sits significantly below the 52-week high, reflecting the uncertainty surrounding the clinical outcomes of its fibroblast-based therapies. The beta value is 1.10, indicating that the stock's price volatility is slightly higher than the broader market, meaning it tends to move with greater intensity than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is N/A, and earnings growth year-over-year is also N/A due to the company's lack of established historical earnings data. The absence of historical revenue and earnings prevents a direct comparison of growth rates, but the current trajectory implies that earnings growth is not yet a function of sales expansion but rather of operational scaling and potential future product launches. FibroBiologics, Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution confirms that the company reinvests all available resources, including its $4.89M cash reserve, into research, development, and commercialization efforts rather than returning capital to shareholders. The overall growth and income profile is characterized by a reliance on capital markets for funding future expansion rather than organic cash flow generation or income distributions. This profile is standard for clinical-stage biotechnology firms that prioritize long-term asset development over short-term shareholder yield.